SCHEMBL3096192

SCHEMBL3096192

CCC[C@H](O)C[C@@H](O)CCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.38
LMNA P02545 1/20 0.38
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 3/20 0.35
NFKB1 P19838 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
FDPS P14324 1/20 0.35
GPR84 Q9NQS5 4/20 0.32
GRIK1 P39086 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096199 1.00 TSHR (0.38) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL16153750 1.00 TSHR (0.38) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL28576046 1.00 TSHR (0.38) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL431429 0.91 LMNA (0.39) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL14337559 0.91 LMNA (0.39) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL3097246 0.91 LMNA (0.39) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL23152428 0.88 THRB (0.48) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL15044037 0.88 TSHR (0.43) TSHRLMNATDP1CYP3A4FDPS
SCHEMBL14581986 0.88 LMNA (0.37) TSHRLMNACHRM1AKR1A1CHRM3
SCHEMBL6281896 0.88 GPR84 (0.41) NFKB1FDPSGPR84FFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109336887-B Benzimidazole chiral heterocyclic compound and preparation method and application thereof 中山大学 2021-12-17 CN claimed
CN-106831862-B Chiral bridged axial chiral monophosphine ligand and preparation method thereof 中山大学 2021-01-15 CN claimed
CN-116947925-A Bridged biphenyl monophosphine ligand containing benzofuran structure, and preparation method and application thereof 中山大学 2023-10-27 CN disclosed
CN-109336887-B Benzimidazole chiral heterocyclic compound and preparation method and application thereof 中山大学 2021-12-17 CN disclosed
CN-106831862-B Chiral bridged axial chiral monophosphine ligand and preparation method thereof 中山大学 2021-01-15 CN disclosed
US-8629268-B2 Cyclisation process of forming a multiple ring compound NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2014-01-14 US disclosed
US-20130046090-A1 CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2013-02-21 US disclosed
US-8227645-B2 Cyclisation process of forming a multiple ring compound NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-07-24 US disclosed
US-20100228058-A1 CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2010-09-09 US disclosed
WO-2007097719-A1 CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228058-A1 CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND DHPS, GGPS1, COASY TSHR 4592/4885LMNA 2075/4885CHRM1 4438/4885
US-20130046090-A1 CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND COASY, AKR1C4, AKR1C2 TSHR 4497/4885LMNA 2022/4885CHRM1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.